A conjugation device includes at least one flow reactor having an inlet and an outlet, the flow reactor(s) being completely filled with a support such as a matrix including 1) chromatography beads, fibers or membranes, and 2) a biologic catalyzer, namely the enzyme ligase, which is immobilized onto this support; a fluid delivery unit in fluid communication with the inlet of the flow reactor(s) and configured to continuously provide the flow reactor(s) with at least one kind of reaction fluid such as antibody and linker-payload according to stages of the conjugation process, the at least one kind of process fluid including a first moiety and a second moiety of a conjugate to be produced; and a fluid collection unit in fluid communication with the outlet of the flow reactor(s) and configured to control collection of fluid flowing out of the outlet of the flow reactor(s) according to the stages of the conjugation process. In a period of enabling the at least one kind of reaction fluid to continuously flow through the flow reactor(s), a conjugation reaction is conducted between the first moiety and the second moiety under catalysis of the ligase to produce the conjugate.

This invention concerns a process to identify consortia of probiotic strains belonging to e.g. the genera Lactobacillus, Bacillus, Pediococcus, and Weissella that can be used in preparations for food supplement, food production, and pharmaceutical applications with the intention to execute a safe and rapid degradation of gluten to non-toxic, non-immunogenic digests.

This invention concerns a process to identify consortia of probiotic strains belonging to e.g. the genera Lactobacillus, Bacillus, Pediococcus, and Weissella that can be used in preparations for food supplement, food production, and pharmaceutical applications with the intention to execute a safe and rapid degradation of gluten to non-toxic, non-immunogenic digests.

Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or “pan-caspase” inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-CoV, MERS-CoV, or SARS-Cov-2.

The present invention relates to a kit for detecting a virus, a composition for detecting a virus and a method for detecting a virus. According to the present invention, viruses may be detected with high efficiency at low cost within a short period of time.

The present invention relates to a kit for detecting a virus, a composition for detecting a virus and a method for detecting a virus. According to the present invention, viruses may be detected with high efficiency at low cost within a short period of time.

Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.

Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.

The invention relates to the field of obesity and related metabolic diseases. More specifically, the invention relates to methods of reducing aggrecanase activity or antigen in mammals in order to enhance brown adipose tissue (BAT) development, to promote conversion of white adipose tissue (WAT) into BAT in vivo, and to limit triglyceride accumulation and steatosis in the liver. The invention also relates to a strategy of neutralization or depletion of ADAMTS5 as a strategy to inhibit adipogenesis and more specifically, the invention relates to a method of reducing aggracanase-2 (ADAMTS5, A Disintegrin and Metalloproteinase with Thrombospondin motif 1; member 5) antigen and/or activity in mammals in order to impair differentiation of precursor cells into mature adipocytes (i.e., adipogenesis).

The present invention relates to an antiviral composition and a screening method thereof for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that occurred in Wuhan, China in 2019. An extract from leaves or unfertilized female flowers of Cannabis sativa L. or its fraction, and the cannabinoids (CBDs) molecules isolated from it have high binding strength and stability to SARS-CoV-2 MP.sup.pro, thereby inhibiting its action as the main protease, to provide a useful lead molecule that can be used alone or in combination with other drugs to treat SARS-CoV-2.